|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121,200.00 KRW | -1.86% |
|
+27.85% | -13.68% |
Company Valuation: OliX Pharmaceuticals, Inc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Market Cap 1 | 355,531 | 2,834,660 | 2,552,817 | - |
| Change | - | 697.3% | -9.94% | - |
| Enterprise Value (EV) | 355,531 | 2,834,660 | 2,552,817 | 2,552,817 |
| Change | - | 697.3% | -9.94% | 0% |
| P/E | -7.98x | -176x | -78.3x | -80.5x |
| PBR | - | - | 40.4x | 41.7x |
| PEG | - | 2.6x | -0.8x | 28.98x |
| Capitalization / Revenue | - | 193x | 319x | 232x |
| EV / Revenue | - | 0x | 319x | 232x |
| EV / EBITDA | - | -0x | -88x | -91.2x |
| EV / EBIT | - | -0x | -82.3x | -85.1x |
| EV / FCF | - | - | -75.1x | -77.4x |
| FCF Yield | - | - | -1.33% | -1.29% |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -2,414 | -800 | -1,548 | -1,505 |
| Distribution rate | - | - | - | - |
| Net sales 1 | - | 14.67 | 8 | 11 |
| EBITDA 1 | - | -27.52 | -29 | -28 |
| EBIT 1 | - | -30.46 | -31 | -30 |
| Net income 1 | -19.1 | -16.23 | -31 | -30 |
| Net Debt | - | - | - | - |
| Reference price 2 | 19,260.00 | 140,400.00 | 121,200.00 | 121,200.00 |
| Nbr of stocks (in thousands) | 18,460 | 20,190 | 21,063 | - |
| Announcement Date | 3/21/25 | 2/12/26 | - | - |
1KRW in Billions2KRW
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -78.29x | - | - | - | 1.81B | |
| 20.56x | 7.11x | 14.62x | 1.42% | 68.12B | |
| 31.44x | 8.03x | 24.45x | 0.05% | 55.18B | |
| -82.4x | 15.59x | -64.97x | -.--% | 28.63B | |
| 30.46x | 5.97x | 15.8x | -.--% | 23.99B | |
| -14.71x | 5.23x | -6.82x | -.--% | 23.53B | |
| 25.47x | 4.76x | 15.94x | -.--% | 18.45B | |
| -1250.29x | 38.99x | -15519.34x | -.--% | 16.44B | |
| 47.61x | 19.33x | 49.78x | 0.08% | 15.83B | |
| 16.76x | 4.95x | 11.57x | -.--% | 13.4B | |
| Average | -125.34x | 12.22x | -1,717.66x | 0.17% | 26.54B | |
| Weighted average by Cap. | -68.15x | 10.40x | -960.50x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A226950 Stock
- Valuation OliX Pharmaceuticals, Inc
Select your edition
All financial news and data tailored to specific country editions
